Not currently recruiting at University of California Health

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

a study on Multiple Myeloma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
completion around

Description

Summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Official Title

ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES

Details

This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.

Keywords

Multiple Myeloma, Elranatamab, Post Trial Access, Roll-over Study, Extension Study, MM-15, MagnetisMM15, BCMA, BCMA antibody, Magnetism, Bispecific antibody, Elrexfio, Plasma Cell Neoplasms

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants must agree to follow the reproductive criteria as outlined in the protocol
  • Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

You CAN'T join if...

  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Locations

  • UC Irvine Health not yet accepting patients
    Orange California 92868 United States
  • Tom Baker Cancer Center accepting new patients
    Calgary Alberta T2N 4N2 Canada
  • Cross Cancer Institute accepting new patients
    Edmonton Alberta T6G 1Z2 Canada

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here.
ID
NCT06057402
Phase
Phase 4 Multiple Myeloma Research Study
Study Type
Interventional
Participants
Expecting 72 study participants
Last Updated